Total submissions: 5
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV000533940 | SCV000651742 | likely benign | Breast-ovarian cancer, familial, susceptibility to, 4 | 2024-08-12 | criteria provided, single submitter | clinical testing | |
Color Diagnostics, |
RCV000584572 | SCV000691334 | likely benign | Hereditary cancer-predisposing syndrome | 2017-08-26 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV000584572 | SCV001182835 | likely benign | Hereditary cancer-predisposing syndrome | 2019-03-07 | criteria provided, single submitter | clinical testing | This alteration is classified as likely benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. |
Women's Health and Genetics/Laboratory Corporation of America, |
RCV003403323 | SCV004121976 | likely benign | not specified | 2023-10-21 | criteria provided, single submitter | clinical testing | |
Prevention |
RCV004751598 | SCV005357388 | likely benign | RAD51D-related disorder | 2024-05-16 | no assertion criteria provided | clinical testing | This variant is classified as likely benign based on ACMG/AMP sequence variant interpretation guidelines (Richards et al. 2015 PMID: 25741868, with internal and published modifications). |